<DOC>
	<DOCNO>NCT00475176</DOCNO>
	<brief_summary>This study examine effectiveness S-adenosyl methionine ( SAMe ) combination peginterferon ribavirin treat hepatitis C virus . One three patient hepatitis C develop cirrhosis liver , lead liver failure liver cancer . SAMe nutritional supplement make naturally cell body act improve body handle stress . In laboratory experiment liver cell , SAMe decrease injury cause liver toxin improve ability interferon block hepatitis C virus . Patients 18 year age old hepatitis C infection respond successfully prior treatment interferon ribavirin peginterferon ribavirin may eligible study . Participants receive follow treatment : - Peginterferon ( give injection ) ribavirin ( take mouth ) 2 week - Washout period ( medication ) 4 week - SAMe ( take mouth ) 2 week - Peginterferon , ribavirin SAMe 12-48 week , depend patient response treatment . Participants thorough physical evaluation begin treatment study 's end . After start treatment , patient return clinic visit blood test weekly first several week , less frequently ( 2-week , 4-week 8-week interval 72 week ) monitor symptom , drug side effect , hepatitis C virus level , liver enzyme level immune response hepatitis C .</brief_summary>
	<brief_title>S-Adenosyl Methionine ( SAMe ) Treat Patients With Chronic Hepatitis C</brief_title>
	<detailed_description>S-adenosyl methionine ( SAMe ) nutritional supplement available over-the-counter formula . It naturally occur , modify amino acid produce virtually cell participate many biochemical pathway major methyl donor may play role intracellular interferon signal . This study assess effect SAMe antiviral response peginterferon ribavirin patient chronic hepatitis C , genotype 1 , fail respond previous course therapy . After screen evaluation , patient receive first course 2 week peginterferon alfa-2a ( 180 microgram weekly ) ribavirin ( 1000-1200 mg daily ) symptom , routine laboratory test , HCV RNA level , natural killer ( NK ) cell activity , lymphocyte interferon-signaling response monitor . After 4-week washout period , patient start SAMe ( 800 mg twice daily ) 2 week begin second course peginterferon ribavirin dose similar monitoring . Therapy continue least 12 week , patient early viral response continue full 48 week . The primary criterion efficacy SAMe improve HCV kinetic response compare first second course peginterferon ribavirin . Secondary endpoint improvement NK cell activity intracellular interferon signal . This pilot study determine whether SAMe improve response peginterferon therapy term intracellular interferon signaling , innate immune response , decline viral level .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>INCLUSION CRITERIA Age 18 year , male female Serum alanine aspartate aminotransferase ( ALT &amp; AST ) activity upper limit normal ( ALT great 41 AST great 31 IU/L ) . Presence antiHCV serum . Presence HCV RNA genotype 1 serum level 10,000 copies/ml . Previous adequate therapy interferon ribavirin peginterferon ribavirin without sustained virological response . An adequate course therapy define least 12 week interferon dose 3 million unit three time weekly peginterferon dose 180 microgram peginterferon alfa2a 1.5 micrograms/kg peginterferon alfa 2b weekly ribavirin start dos least 1000 mg daily . Patients initiated therapy dos , require dose modification due side effect also eligible . Written informed consent : Patients inform risk/benefits sideeffects medication use protocol advise research blood drawn clinic visit . They give ample time read consent form ask protocol related question . Once do , patient 's signature obtain consent form enroll protocol . EXCLUSION CRITERIA Evidence form liver disease . Hepatitis B define presence hepatitis B surface antigen ( HBsAg ) serum . Primary sclerosing cholangitis define liver histology . Wilson disease define ceruloplasmin limit normal liver histology consistent Wilson disease . Autoimmune hepatitis define antinuclear antibody ( ANA ) 3 EU great ( ELISA ) liver histology consistent autoimmune hepatitis previous response immunosuppressive therapy autoimmune hepatitis . Alpha1antitrypsin deficiency define alpha1antitrypsin level less normal liver histology consistent alpha1antitrypsin deficiency . Hemochromatosis define presence 3+ 4+ stainable iron liver biopsy homozygosity C282Y compound heterozygosity C282Y/H63D . Patients iron saturation index great 45 % serum ferritin level great 300 ng/ml men great 250 ng/ml woman undergo genetic test C282Y H63D . Drug induce liver disease define basis typical exposure history . Bile duct obstruction suggest image study do within previous six month . Decompensated liver disease , mark bilirubin great 4 mg/dl , albumin less 3.0 gm/l , prothrombin time great 2 sec prolong , ChildPugh score 7 great history bleed esophageal varix , ascites hepatic encephalopathy . Patients ALT level great 1000 U/L ( great 25 time upper limit normal range ) enrol may follow three determination level . Significant systemic major illness liver disease , include congestive heart failure , coronary artery disease , cerebrovascular disease , pulmonary disease hypoxia , renal failure , organ transplantation , serious psychiatric disease include depression , malignancy condition opinion investigator would preclude treatment . Pre exist , severe bone marrow compromise ; anemia ( hematocrit le 34 % ) , neutropenia ( less 1000 polymorphonuclear cells/mm ( 3 ) ) thrombocytopenia ( le 70,000 cells/mm ( 3 ) ) . Serious autoimmune disease , opinion investigator , might worsen interferon therapy , lupus erythematous , rheumatoid arthritis Crohn 's disease Known HIV infection . Active substance abuse , alcohol , inhale injection drug within previous one year . Pregnancy , lactation woman child bear potential spouse woman , inability practice adequate contraception , define vasectomy men , tubal ligation woman , use condom spermicide , birth control pills/depot injection , intrauterine device . Evidence hepatocellular carcinoma ; either alphafetoprotein ( AFP ) level great 50 ng/ml ( normal less 9 ng/ml ) and/or ultrasound ( image study ) demonstrate mass suggestive liver cancer . Immunosuppressive therapy either corticosteroid ( 5 mg prednisone daily ) major immunosuppressive agent ( azathioprine 6mercaptopurine ) . Clinical gout presentation . History hypersensitivity reaction Sadenosyl methionine . Serum creatinine great 1.5mg/dl men great 1.4 mg/dl woman . Any condition , opinion investigator would impede patient 's participation compliance study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Hepatitis C Virus Genotype 1</keyword>
	<keyword>Non-Responders</keyword>
	<keyword>SAMe</keyword>
	<keyword>Natural Killer Cells</keyword>
	<keyword>Interferon Signaling</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>Peginterferon</keyword>
	<keyword>Hemolysis</keyword>
	<keyword>STAT</keyword>
	<keyword>Hepatitis C</keyword>
</DOC>